Oryzon Genomics ORYZF Stock
Oryzon Genomics Price Chart
Oryzon Genomics ORYZF Financial and Trading Overview
| Oryzon Genomics stock price | 3.36 USD |
| Previous Close | 3.36 USD |
| Open | 3.45 USD |
| Bid | 3.13 USD x 10000 |
| Ask | 3.69 USD x 20000 |
| Day's Range | 3.45 - 3.45 USD |
| 52 Week Range | 3.25 - 4.38 USD |
| Volume | 100 USD |
| Avg. Volume | 384 USD |
| Market Cap | 275.38M USD |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.04 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10 USD |
ORYZF Valuation Measures
| Enterprise Value | 256.57M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 17.873259 |
| Price/Book (mrq) | 1.9328865 |
| Enterprise Value/Revenue | 16.653 |
| Enterprise Value/EBITDA | -43.922 |
Trading Information
Oryzon Genomics Stock Price History
| Beta (5Y Monthly) | 0.44 |
| 52-Week Change | 2.43% |
| S&P500 52-Week Change | 18.67% |
| 52 Week High | 4.38 USD |
| 52 Week Low | 3.25 USD |
| 50-Day Moving Average | 3.57 USD |
| 200-Day Moving Average | 3.47 USD |
ORYZF Share Statistics
| Avg. Volume (3 month) | 384 USD |
| Avg. Daily Volume (10-Days) | 2.15K USD |
| Shares Outstanding | 81.96M |
| Float | 61.45M |
| Short Ratio | N/A |
| % Held by Insiders | 20.14% |
| % Held by Institutions | 0.93% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -15.76% |
| Operating Margin (ttm) | 30.76% |
| Gross Margin | 97.75% |
| EBITDA Margin | -37.91% |
Management Effectiveness
| Return on Assets (ttm) | -2.66% |
| Return on Equity (ttm) | -2.076% |
Income Statement
| Revenue (ttm) | 15.41M USD |
| Revenue Per Share (ttm) | 0.2 USD |
| Quarterly Revenue Growth (yoy) | 106.00% |
| Gross Profit (ttm) | 15.06M USD |
| EBITDA | -5841454 USD |
| Net Income Avi to Common (ttm) | -2428399 USD |
| Diluted EPS (ttm) | -0.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 14.69M USD |
| Total Cash Per Share (mrq) | 0.19 USD |
| Total Debt (mrq) | 10.8M USD |
| Total Debt/Equity (mrq) | 9.02 USD |
| Current Ratio (mrq) | 1.596 |
| Book Value Per Share (mrq) | 1.7383327 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -4910950 USD |
| Levered Free Cash Flow (ttm) | -16363554 USD |
Profile of Oryzon Genomics
| Country | United States |
| State | N/A |
| City | Cornellà de Llobregat |
| Address | Sant Ferran 74 |
| ZIP | 08940 |
| Phone | 34 93 515 13 13 |
| Website | https://www.oryzon.com/en |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 46 |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Q&A For Oryzon Genomics Stock
What is a current ORYZF stock price?
Oryzon Genomics ORYZF stock price today per share is 3.36 USD.
How to purchase Oryzon Genomics stock?
You can buy ORYZF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Oryzon Genomics?
The stock symbol or ticker of Oryzon Genomics is ORYZF.
Which industry does the Oryzon Genomics company belong to?
The Oryzon Genomics industry is Biotechnology.
How many shares does Oryzon Genomics have in circulation?
The max supply of Oryzon Genomics shares is 81.96M.
What is Oryzon Genomics Price to Earnings Ratio (PE Ratio)?
Oryzon Genomics PE Ratio is now.
What was Oryzon Genomics earnings per share over the trailing 12 months (TTM)?
Oryzon Genomics EPS is -0.04 USD over the trailing 12 months.
Which sector does the Oryzon Genomics company belong to?
The Oryzon Genomics sector is Healthcare.
